Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Trillium Therapeutics Inc.    TRIL   CA89620X5064

TRILLIUM THERAPEUTICS INC.

(TRIL)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 11/23 04:00:00 pm
23.1 CAD   -0.99%
11/17TSX pushed down by energy stocks
RE
11/16Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results
GL
11/13TSX rises 0.68% to 16,695.65
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
21.99(c) 23.31(c) 22.95(c) 23.33(c) 23.1(c) Last
383 532 402 908 350 071 301 937 304 577 Volume
+10.84% +6.00% -1.54% +1.66% -0.99% Change
More quotes
Financials
Sales 2020 0,15 M 0,12 M 0,12 M
Net income 2020 -263 M -201 M -201 M
Net Debt 2020 - - -
P/E ratio 2020 -7,78x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -109 M -83,1 M -83,1 M
Net Debt 2021 - - -
P/E ratio 2021 -23,3x
Yield 2021 -
Capitalization 2 350 M 1 798 M 1 796 M
Capi. / Sales 2020 15 468x
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 99,9%
More Financials
Company
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory... 
More about the company
Notations Surperformance© of Trillium Therapeutics Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about TRILLIUM THERAPEUTICS INC.
11/17TSX pushed down by energy stocks
RE
11/16Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Resu..
GL
11/13TSX rises 0.68% to 16,695.65
RE
11/12Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
GL
11/02Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer
GL
11/02Trillium Therapeutics Announces Formation of Scientific Advisory Board
GL
10/30TSX slips as energy stocks weigh, virus cases surge
RE
10/30TSX slips as energy stocks weigh, virus cases surge
RE
10/05Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trad..
GL
09/22TSX rises 1.01% to 16,142.89
RE
09/18Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Direct..
GL
09/16Trillium Closes US$150 Million Public Offering of Common Shares
GL
09/10Trillium Announces Pricing of US$130 Million Public Offering of Common Shares
GL
09/09Trillium Announces Proposed Public Offering of Common Shares
GL
09/09TRILLIUM THERAPEUTICS : SEC Filing (424B5) - Supplemental Prospectus
PU
More news
News in other languages on TRILLIUM THERAPEUTICS INC.

- No features available -

More news
Chart TRILLIUM THERAPEUTICS INC.
Duration : Period :
Trillium Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRILLIUM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 22,30 CAD
Last Close Price 23,33 CAD
Spread / Highest target 56,9%
Spread / Average Target -4,40%
Spread / Lowest Target -65,7%
EPS Revisions
Managers
NameTitle
Jan Skvarka President, Chief Executive Officer & Director
Robert L. Kirkman Chairman
James T. Parsons Chief Financial Officer & Secretary
Robert A. Uger Chief Scientific Officer
Kathleen Large Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
TRILLIUM THERAPEUTICS INC.1,654.14%1 798
GILEAD SCIENCES, INC.-7.49%75 350
VERTEX PHARMACEUTICALS-1.71%55 963
REGENERON PHARMACEUTICALS38.15%54 750
WUXI APPTEC CO., LTD.65.81%40 457
BEIGENE, LTD.71.43%25 903